ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

ASPIRIN VERSUS PLACEBO IN PREGNANCIES AT HIGH RISK FOR PRETERM PREECLAMPSIA

Dr Ramsha Ghias, Dr. Muhammad Jazib Khilji, Dr. Rana Muhammad Talha

Objective: To compare the effects of Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia Design: double-blind randomization, placebo-controlled trial Patient(s): The study comprised a total of 121 singleton pregnant women with high risk of preterm preeclampsia Intervention(s): start either aspirin 100 mg/day or placebo, which were continued until 35 weeks of gestation or delivery, whichever occurred first. Main Outcome Measure(s): preterm preeclampsia Result(s): Preterm preeclampsia occurred in 13 participants 1.5% in the aspirin group, as compared with 4.6% in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74; P=0.004). Conclusion: The administration of aspirin at a dose of 150 mg per day from 12 to 13 +6 weeks of gestation until delivery resulted in a significantly lower incidence of preterm preeclampsia than that with placebo. Key words: aspirin, placebo, pregnancy, preterm preeclampsia.

FULL TEXT